Daratumumab and Hyaluronidase-fihj Approved for Light Chain Amyloidosis
The combination of daratumumab and hyaluronidase-fihj and bortezomib, cyclophosphamide, and dexamethasone (D-VCd) was granted accelerated approval for the treatment of adults with newly diagnosed...
Charting the Myeloma Immunotherapy Landscape
A bevy of forthcoming immunotherapies for multiple myeloma over the next few years raises hopes, as well as questions about combinations, sequencing, and potential...
Examining Outcomes Among Hispanic Patients With Multiple Myeloma
Hispanic and non-Hispanic Black patients with multiple myeloma (MM) more often present with disease at a younger age and with significant renal dysfunction. These...
Idecabtagene Vicleucel Promising in Pretreated Myeloma
Three-quarters of patients with heavily pretreated multiple myeloma responded to treatment with the B-cell maturation antigen (BCMA)−targeted chimeric antigen receptor (CAR) T-cell therapy idecabtagene...
Teclistamab Shows Promise for Myeloma in Phase I Trial
Approximately three-quarters of patients with relapsed and/or refractory multiple myeloma (MM) responded to treatment with the bispecific antibody teclistamab, according to results from a...
The Future of Chronic Graft-Versus-Host Disease
An Update From the 3rd NIH Chronic GVHD Consensus Conference
In this edition, Steven Pavletic, MD, and Kirk Schultz, MD, report on the progress and...
BOSTON: Selinexor Improves Progression-Free Survival in Relapsed/Refractory Myeloma
The combination of once-weekly selinexor with bortezomib and dexamethasone (SVd) demonstrated a 30% reduction in the risk of disease progression or death, compared with...
Examining Immune Response in Patients with Hematologic Malignancy After COVID-19 Infection
Patients with a history of a hematologic malignancy who survive COVID-19 infection have similar immune responses against the virus following infection compared with people...
Phase III Trial Supports Efficacy of Subcutaneous Daratumumab in Relapsed/Refractory Myeloma
Patients with relapsed/refractory multiple myeloma (MM) who were treated with a combination of subcutaneous daratumumab plus pomalidomide-dexamethasone (Pd) had a 37% lower risk of...
CARTITUDE-1: Myeloma CAR T-Cell Therapy Produces Deep and Durable Responses
A single low-dose infusion of ciltacabtagene autoleucel (cilta-cel), an autologous chimeric antigen receptor (CAR) T-cell therapy, was safe and associated with early, deep, and...
Current Issue
March 2021 Volume 7 Issue 4
This issue examines blood services across the globe, the repercussions of increased patient access to medical information, and more.